Barclays analyst Matt Miksic maintained a Sell rating on ZimVie Inc (ZIMV – Research Report) today and set a price target of $16.00. The company’s shares closed yesterday at $16.97.
According to TipRanks, Miksic is a 5-star analyst with an average return of 7.2% and a 61.33% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Medtronic, Globus Medical, and LivaNova.
ZimVie Inc has an analyst consensus of Moderate Sell, with a price target consensus of $16.00.
The company has a one-year high of $20.91 and a one-year low of $6.52. Currently, ZimVie Inc has an average volume of 347.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ZimVie Inc (ZIMV) Company Description:
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions.
